Opatanol Eye Drops 5ml vial 1mg/ml,Opatanol Collirio Flaconcino 5ml 1mg/ml, Novartis Pharma S.p.A.

“ACTIVE ingredients: Olopatadina. Excipients: Benzalkonium chloride, sodium chloride, sodium phosphate dodecaidrat or (E339), hydrochloric acid (E507) (for pH correction), sodium hydroxy ido (E524) (for pH correction), purified water.
INDICATIONS: Treatment of signs and eye symptoms of allergic conjunctivitis size S.
CONTRAINDICATIONS/EFF.SECONDARY: Hypersensitivity to the active substance or to any of the ingredients listed.
DOSAGE: The dose is a drop into the conjunctival sac of the part/eye/i affection to/twice a day (every 8 hours). Treatment may be extended anointing up to four months if deemed necessary. Use in anzhero ni: not so, the dose needs to be changed. Pediatric population: the product can be used in pediatric patients (from 3 years of age) at the same dose used for adults. The safety and effectiveness of this drug in children under 3 years of age have not yet been determined. No data available. Use in patients with sufficient liver and kidney function Olopatadina, in the form of eye drops, has not been studied in patients with kidney or liver disease. All in case of hepatic or renal failure is not considered necessary or change the dosage. Directions for use: For use in oft miko only. Once the cap has been removed, if the safety ring has become loose, remove it before using the product. In order to prevent contamination of the dropper tip and the solution, be careful not to touch the eyelids, the area around you, or other surfaces with the dropper tip of the bottle. Keep l bottle tightly closed when not in use. In the case of therapy with the committee with other topical medicinal products, you should leave int erver five minutes between the dose and the next one. Eye ointments should be administered last.
STORAGE: This drug does not require special ion storage conditions.
Special INSTRUCTIONS: the drug is an antiallergic/antihistamine that, although administered externally, is absorbed at the systemic level. In case of severe reactions or hypersensitivity, treatment should be discontinued. This medicine contains benzalkonium chloride, which may cause eye irritation. It has been reported that benzalkonium chloride may cause rate cheratopatia and/or toxic ulcerative cheratopatia. Patients with dry eye syndrome or other conditions in which the cornea is compromised should be closely monitored if using fr-equense or long-term. Contact Lenses And benzalkonium is a known company ion to discolor soft contact lenses. Avoid contact with soft contact lenses. Patients should be instructed to remove contact lenses before administering Irina adhesive and to wait at least 15 minutes after instillation before inserting contact lenses.
INTERACTIONS: Studies have not been conducted on interactions with other medicinal products. Stu in vitro showed that olopatadina does not block metabolic reactions involving isoenzyme 1A2, 2C8, 2C9, 2C19, 2D6, 2E 1 and 3A4 of cytochrome P-450. These results indicate that this is unlikely, or that olopatadina causes metabolic interaction with other active substances administered concomitantly.
SIDE EFFECTS: The following adverse reactions have been reported during study of CL injection and post-marketing data and are classified according to the following convention body: very common (>=1/10), common (>=1/100 a =1/1,000 a= 1/10,000 to”